Related Experiment Videos
Failure of phenobarbitone to prevent febrile convulsions
Insights
Daily phenobarbitone treatment did not significantly prevent further febrile convulsions in young children. Focus should shift to rapid emergency response for convulsion termination to prevent brain damage.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Febrile convulsions are common in young children.
- Preventing recurrent febrile seizures is crucial to avoid potential neurological damage.
Purpose of the Study:
- To evaluate the efficacy of daily phenobarbitone in preventing recurrent febrile convulsions in children.
- To assess the impact of regular phenobarbitone intake on seizure recurrence.
Main Methods:
- A randomized controlled trial involving 165 children aged 6 months to 3 years with first-time febrile convulsions.
- Children were assigned to daily phenobarbitone or a control group for a 6-month follow-up period.
- Plasma phenobarbitone concentrations were monitored in treated children.
Main Results:
- Phenobarbitone treatment did not show a significant reduction in further convulsions compared to the control group (10 vs. 14).
- Only 49 children took phenobarbitone regularly; among them, 4 experienced further febrile convulsions, a rate not significantly different from controls.
- In children experiencing repeat convulsions, plasma phenobarbitone levels were often above 69 mumol/l.
Conclusions:
- Regular phenobarbitone administration appears ineffective in preventing recurrent febrile convulsions.
- Emphasis should be placed on developing emergency services for prompt termination of febrile convulsions to prevent irreversible brain damage.
Abstract:
One-hundred-sixty-five children without known neurological disorder who presented with their first febrile convulsion between the ages of six months and three years were assigned to daily phenobarbitone treatment or to a control group and followed up at a special clinic for six months. One-hundred-and-sixty-one-one children completed the trial, and of the 88 children assigned to phenobarbitone treatment 10 had further convulsions during this period compared with 14 of the 73 control children. Only 49 of those assigned to phenobarbitone took the drug regularly throughout the trial, and four of these had further febrile convulsions, a proportion not significantly different from that in the controls. All four had mean plasma phenobarbitone concentrations over 69 mumol/l (16 mug/ml) during the trial and in three the plasma concentration was at or over this figure within eight hours over 69 mumol/l (16 mug/ml) during the trial and in three the plasma concentration was at or over this figure within eight hours of the repeat convulsion. Regular phenobarbitone does not seem to prevent febrile convulsions. Attention should instead be directed to organising emergency services to allow early termination of fevrile convulsions, whether first or subsequent, to prevent irreversible brain damage.